|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isharwal S and Konety B: Non-muscle
invasive bladder cancer risk stratification. Indian J Urol.
31:289–296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and
Kurth K: Predicting recurrence and progression in individual
patients with stage Ta T1 bladder cancer using EORTC risk tables: A
combined analysis of 2,596 patients from seven EORTC trials. Eur
Urol. 49:466–465, Discussion 475-467. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi T: Understanding the biology of
urothelial cancer metastasis. Asian J Urol. 3:211–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yadav L, Puri N, Rastogi V, Satpute P,
Ahmad R and Kaur G: Matrix metalloproteinases and cancer-roles in
threat and therapy. Asian Pac J Cancer Prev. 15:1085–1091. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nannuru KC, Futakuchi M, Varney ML,
Vincent TM, Marcusson EG and Singh RK: Matrix metalloproteinase
(MMP)-13 regulates mammary tumor-induced osteolysis by activating
MMP9 and transforming growth factor-beta signaling at the
tumor-bone interface. Cancer Res. 70:3494–3504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verma S, Kesh K, Gupta A and Swarnakar S:
An overview of matrix metalloproteinase 9 polymorphism and gastric
cancer risk. Asian Pac J Cancer Prev. 16:7393–7400. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Malcherczyk D, Heyse TJ, El-Zayat BF,
Kunzke V, Moll R, Fuchs-Winkelmann S and Paletta JRJ: Expression of
MMP-9 decreases metastatic potential of Chondrosarcoma: An
immunohistochemical study. BMC Musculoskelet Disord. 19:92018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H, Qiu Z, Li F and Wang C: The
relationship between MMP-2 and MMP-9 expression levels with breast
cancer incidence and prognosis. Oncol Lett. 14:5865–5870.
2017.PubMed/NCBI
|
|
12
|
Reis ST, Leite KR, Piovesan LF,
Pontes-Junior J, Viana NI, Abe DK, Crippa A, Moura CM, Adonias SP,
Srougi M and Dall'Oglio MF: Increased expression of MMP-9 and IL-8
are correlated with poor prognosis of Bladder Cancer. BMC Urol.
12:182012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou W, Yu X, Sun S, Zhang X, Yang W,
Zhang J, Zhang X and Jiang Z: Increased expression of MMP-2 and
MMP-9 indicates poor prognosis in glioma recurrence. Biomed
Pharmacother. 118:1093692019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ranganathan K and Sivasankar V:
MicroRNAs-Biology and clinical applications. J Oral Maxillofac
Pathol. 18:229–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eichhorn SW, Guo H, McGeary SE,
Rodriguez-Mias RA, Shin C, Baek D, Hsu SH, Ghoshal K, Villén J and
Bartel DP: mRNA destabilization is the dominant effect of mammalian
microRNAs by the time substantial repression ensues. Mol Cell.
56:104–115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hammond SM: MicroRNAs as oncogenes. Curr
Opin Genet Dev. 16:4–9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lodygin D, Tarasov V, Epanchintsev A,
Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking
H: Inactivation of miR-34a by aberrant CpG methylation in multiple
types of cancer. Cell Cycle. 7:2591–2600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chim CS, Wong KY, Qi Y, Loong F, Lam WL,
Wong LG, Jin DY, Costello JF and Liang R: Epigenetic inactivation
of the miR-34a in hematological malignancies. Carcinogenesis.
31:745–750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang C, Yao Z, Zhu M, Ma X, Shi T, Li H,
Wang B, Ouyang J and Zhang X: Inhibitory effects of microRNA-34a on
cell migration and invasion of invasive urothelial bladder
carcinoma by targeting Notch1. J Huazhong Univ Sci Technolog Med
Sci. 32:375–382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu G, Yao W, Xiao W, Li H, Xu H and Lang
B: MicroRNA-34a functions as an anti-metastatic microRNA and
suppresses angiogenesis in bladder cancer by directly targeting
CD44. J Exp Clin Cancer Res. 33:7792014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou J, Zhou W, Kong F, Xiao X, Kuang H
and Zhu Y: microRNA-34a overexpression inhibits cell migration and
invasion via regulating SIRT1 in hepatocellular carcinoma. Oncol
Lett. 14:6950–6954. 2017.PubMed/NCBI
|
|
23
|
Yang S, Li Y, Gao J, Zhang T, Li S, Luo A,
Chen H, Ding F, Wang X and Liu Z: MicroRNA-34 suppresses breast
cancer invasion and metastasis by directly targeting Fra-1.
Oncogene. 32:4294–4303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin CJ, Gong HY, Tseng HC, Wang WL and Wu
JL: miR-122 targets an anti-apoptotic gene, Bcl-w, in human
hepatocellular carcinoma cell lines. Biochem Biophys Res Commun.
375:315–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin JF, Lin YC, Yang SC, Tsai TF, Chen HE,
Chou KY and Hwang TI: Autophagy inhibition enhances RAD001-induced
cytotoxicity in human bladder cancer cells. Drug Des Devel Ther.
10:1501–1513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Liao Y and Tang L: MicroRNA-34
family: A potential tumor suppressor and therapeutic candidate in
cancer. J Exp Clin Cancer Res. 38:532019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inamura K: Bladder cancer: New insights
into its molecular pathology. Cancers (Basel). 10:1002018.
View Article : Google Scholar
|
|
29
|
Li L, Yuan L, Luo J, Gao J, Guo J and Xie
X: MiR-34a inhibits proliferation and migration of breast cancer
through down-regulation of Bcl-2 and SIRT1. Clin Exp Med.
13:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yaxley JP: Urinary tract cancers: An
overview for general practice. J Family Med Prim Care. 5:533–538.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen Z, Shen T, Wientjes MG, O'Donnell MA
and Au JL: Intravesical treatments of bladder cancer: Review. Pharm
Res. 25:1500–1510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Di Pierro GB, Gulia C, Cristini C,
Fraietta G, Marini L, Grande P, Gentile V and Piergentili R:
Bladder cancer: A simple model becomes complex. Curr Genomics.
13:395–415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu J, Xiong G, Trinkle C and Xu R:
Integrated extracellular matrix signaling in mammary gland
development and breast cancer progression. Histol Histopathol.
29:1083–1092. 2014.PubMed/NCBI
|
|
35
|
Quintero-Fabián S, Arreola R,
Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V,
Lara-Riegos J, Ramírez-Camacho MA and Alvarez-Sánchez ME: Role of
matrix metalloproteinases in angiogenesis and cancer. Front Oncol.
9:13702019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ueda J, Kajita M, Suenaga N, Fujii K and
Seiki M: Sequence-specific silencing of MT1-MMP expression
suppresses tumor cell migration and invasion: Importance of MT1-MMP
as a therapeutic target for invasive tumors. Oncogene.
22:8716–8722. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lakka SS, Rajan M, Gondi C, Yanamandra N,
Chandrasekar N, Jasti SL, Adachi Y, Siddique K, Gujrati M, Olivero
W, et al: Adenovirus-mediated expression of antisense MMP-9 in
glioma cells inhibits tumor growth and invasion. Oncogene.
21:8011–8019. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hofmann UB, Westphal JR, Zendman AJ,
Becker JC, Ruiter DJ and van Muijen GN: Expression and activation
of matrix metalloproteinase-2 (MMP-2) and its co-localization with
membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with
melanoma progression. J Pathol. 191:245–256. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mehner C, Hockla A, Miller E, Ran S,
Radisky DC and Radisky ES: Tumor cell-produced matrix
metalloproteinase 9 (MMP-9) drives malignant progression and
metastasis of basal-like triple negative breast cancer. Oncotarget.
5:2736–2749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vihinen P and Kähäri VM: Matrix
metalloproteinases in cancer: Prognostic markers and therapeutic
targets. Int J Cancer. 99:157–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Itoh T, Tanioka M, Yoshida H, Yoshioka T,
Nishimoto H and Itohara S: Reduced angiogenesis and tumor
progression in gelatinase A-deficient mice. Cancer Res.
58:1048–1051. 1998.PubMed/NCBI
|
|
43
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Skaftnesmo KO, Prestegarden L, Micklem DR
and Lorens JB: MicroRNAs in tumorigenesis. Curr Pharm Biotechnol.
8:320–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu X, Liu X, Wu Y, Fang Z, Wu Q, Wu C,
Hao Y, Yang X, Zhao J, Li J, et al: MicroRNA-34a attenuates
metastasis and chemoresistance of bladder cancer cells by targeting
the TCF1/LEF1 axis. Cell Physiol Biochem. 48:87–98. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ding ZS, He YH, Deng YS, Peng PX, Wang JF,
Chen X, Zhao PY and Zhou XF: MicroRNA-34a inhibits bladder cancer
cell migration and invasion, and upregulates PTEN expression. Oncol
Lett. 18:5549–5554. 2019.PubMed/NCBI
|
|
47
|
Yang L, Song X, Zhu J, Li M, Ji Y, Wu F,
Chen Y, Cui X, Hu J, Wang L, et al: Tumor suppressor microRNA-34a
inhibits cell migration and invasion by targeting
MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int J
Oncol. 51:378–388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhao H, Xing F, Yuan J, Li Z and Zhang W:
Sevoflurane inhibits migration and invasion of glioma cells via
regulating miR-34a-5p/MMP-2 axis. Life Sci. 256:1178972020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Di Martino MT, Leone E, Amodio N, Foresta
U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli
E, et al: Synthetic miR-34a mimics as a novel therapeutic agent for
multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res.
18:6260–6270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yan D, Zhou X, Chen X, Hu DN, Dong XD,
Wang J, Lu F, Tu L and Qu J: MicroRNA-34a inhibits uveal melanoma
cell proliferation and migration through downregulation of c-Met.
Invest Ophthalmol Vis Sci. 50:1559–1565. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Trang P, Wiggins JF, Daige CL, Cho C,
Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ: Systemic
delivery of tumor suppressor microRNA mimics using a neutral lipid
emulsion inhibits lung tumors in mice. Mol Ther. 19:1116–1122.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dyrskjøt L, Ostenfeld MS, Bramsen JB,
Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL,
Andersen CL, Zieger K, et al: Genomic profiling of microRNAs in
bladder cancer: miR-129 is associated with poor outcome and
promotes cell death in vitro. Cancer Res. 69:4851–4860. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y,
Zhang Y, Li X, Fan Y, Chen J and Zhang X: MicroRNAs with prognostic
significance in bladder cancer: A systematic review and
meta-analysis. Sci Rep. 7:56192017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Al-Husseini MJ, Kunbaz A, Saad AM, Santos
JV, Salahia S, Iqbal M and Alahdab F: Trends in the incidence and
mortality of transitional cell carcinoma of the bladder for the
last four decades in the USA: A SEER-based analysis. BMC Cancer.
19:462019. View Article : Google Scholar : PubMed/NCBI
|
